Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berberil N is an ophthalmic decongestant containing tetryzoline hydrochloride, a small molecule alpha-sympathomimetic agent. It is used to provide rapid relief from eye redness and irritation caused by non-specific environmental factors such as smoke, wind, chlorinated water, and light, as well as allergic conjunctivitis. The drug works by stimulating alpha-adrenergic receptors in the conjunctival blood vessels, leading to vasoconstriction and reduced hyperemia. Developed by Dr. Gerhard Mann (a Bausch + Lomb company), it is administered topically as eye drops and is approved for use in adults and children from 2 years of age.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Berberil N.